Título : |
Real-world analysis of treatment patterns and clinical outcomes in patients with newly diagnosed chronic lymphocytic leukemia from seven Latin American countries |
Tipo de documento : |
documento electrónico |
Autores : |
Kenny Mauricio Gálvez Cárdenas, |
Fecha de publicación : |
2020 |
Títulos uniformes : |
Hematology
|
Idioma : |
Inglés (eng) |
Palabras clave : |
Latin America chronic lymphocytic leukemia treatment pattern real-world evidence fludarabine progression-free survival chlorambucil overall survival |
Resumen : |
Objective: To describe chronic lymphocytic leukemia (CLL) treatment patterns and patient outcomes in Latin America. Methods: This chart review study (NCT02559583; 2008–2015)evaluated time to progression (TTP) and overall survival (OS) outcomes among patients with CLL who initiate done (n = 261) to two (n = 96) lines of therapy (LOT) since diagnosis. Differences in TTP and OS were assessed by Kaplan-Meier analysis, with a log-rank test for statistical significance. Association between therapeutic regimen and risk for disease progression or death was estimated using Cox proportional hazard regression. Results: The most commonly prescribed therapies in both LOTs were chlorambucil-, followed by fludarabine- and cyclophosphamide (C)/CHOP-based therapies. Chlorambucil- and C/CHOP-based therapies were largely prescribed to elderly patients (≥65 years) while fludarabine-based therapy was predominantly used by younger patients (≤65 years). In LOT1, relative to chlorambucil-administered patients, those prescribed fludarabine-based therapies had lower risk of disease progression (hazard ratio [HR] and 95% confidence interval [CI] 0.32 [0.19–0.54]), whereas C/CHOP-prescribed patients had higher risk (HR 95%CI 1.88 [1.17–3.04]). Similar results were observed in LOT2. There was no difference in OS between treatments in both LOTs. Discussion: Novel therapies such as kinase inhibitors were rarely prescribed in LOT1 or LOT2in Latin America. The greater TTP observed forfludarabine-based therapies could be attributed to the fact that fludarabine-based therapies are predominantly administered to young and healthy patients. Conclusion: Chlorambucil-based therapy, which has limited benefits, is frequently prescribed in Latin America. Prescribing novel agents for fludarabine-based therapy-ineligible patients with CLL is the need of the hour. |
Mención de responsabilidad : |
Carlos Chiattone, David Gomez-Almaguer, Carolina Pavlovsky, Elena J. Tuna-Aguilar, Ana L. Basquiera, Luis Palmer, Danielle Leao Cordeiro de Farias, Sergio Schusterschitz da Silva Araujo, Kenny Mauricio Galvez-Cardenas, Alvaro Gomez Diaz, Jennifer H. Lin, Yen-wen Chen, Gerardo Machnicki, Michelle Mahler, Lori Parisi & Paula Barreyro |
Referencia : |
Hematology. 2020 Dec;25(1):366-371. |
DOI (Digital Object Identifier) : |
10.1080/16078454.2020.1833504 |
PMID : |
33095117 |
Derechos de uso : |
CC BY-NC |
En línea : |
https://www.tandfonline.com/doi/full/10.1080/16078454.2020.1833504 |
Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5152 |
Real-world analysis of treatment patterns and clinical outcomes in patients with newly diagnosed chronic lymphocytic leukemia from seven Latin American countries [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, . - 2020. Obra : HematologyIdioma : Inglés ( eng) Palabras clave : |
Latin America chronic lymphocytic leukemia treatment pattern real-world evidence fludarabine progression-free survival chlorambucil overall survival |
Resumen : |
Objective: To describe chronic lymphocytic leukemia (CLL) treatment patterns and patient outcomes in Latin America. Methods: This chart review study (NCT02559583; 2008–2015)evaluated time to progression (TTP) and overall survival (OS) outcomes among patients with CLL who initiate done (n = 261) to two (n = 96) lines of therapy (LOT) since diagnosis. Differences in TTP and OS were assessed by Kaplan-Meier analysis, with a log-rank test for statistical significance. Association between therapeutic regimen and risk for disease progression or death was estimated using Cox proportional hazard regression. Results: The most commonly prescribed therapies in both LOTs were chlorambucil-, followed by fludarabine- and cyclophosphamide (C)/CHOP-based therapies. Chlorambucil- and C/CHOP-based therapies were largely prescribed to elderly patients (≥65 years) while fludarabine-based therapy was predominantly used by younger patients (≤65 years). In LOT1, relative to chlorambucil-administered patients, those prescribed fludarabine-based therapies had lower risk of disease progression (hazard ratio [HR] and 95% confidence interval [CI] 0.32 [0.19–0.54]), whereas C/CHOP-prescribed patients had higher risk (HR 95%CI 1.88 [1.17–3.04]). Similar results were observed in LOT2. There was no difference in OS between treatments in both LOTs. Discussion: Novel therapies such as kinase inhibitors were rarely prescribed in LOT1 or LOT2in Latin America. The greater TTP observed forfludarabine-based therapies could be attributed to the fact that fludarabine-based therapies are predominantly administered to young and healthy patients. Conclusion: Chlorambucil-based therapy, which has limited benefits, is frequently prescribed in Latin America. Prescribing novel agents for fludarabine-based therapy-ineligible patients with CLL is the need of the hour. |
Mención de responsabilidad : |
Carlos Chiattone, David Gomez-Almaguer, Carolina Pavlovsky, Elena J. Tuna-Aguilar, Ana L. Basquiera, Luis Palmer, Danielle Leao Cordeiro de Farias, Sergio Schusterschitz da Silva Araujo, Kenny Mauricio Galvez-Cardenas, Alvaro Gomez Diaz, Jennifer H. Lin, Yen-wen Chen, Gerardo Machnicki, Michelle Mahler, Lori Parisi & Paula Barreyro |
Referencia : |
Hematology. 2020 Dec;25(1):366-371. |
DOI (Digital Object Identifier) : |
10.1080/16078454.2020.1833504 |
PMID : |
33095117 |
Derechos de uso : |
CC BY-NC |
En línea : |
https://www.tandfonline.com/doi/full/10.1080/16078454.2020.1833504 |
Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5152 |
| |